Duloxetine Hcl Capsule, Delayed Release Pellets
Product Images NDC 80425-0086

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine HCl 30mg Cap Qty 30 Ndc 80425 0086

Label for Duloxetine HCL DR 30 mg capsules, delayed release pellets, 30 count, by Advanced Rx of Tennessee, LLC. The label includes the NDC 80425-0086 and batch information, with storage instructions to keep at 20°-25°C (68°-77°F). Contains a comparison reference to Cymbalta.*

FDA Label Image

Duloxetine HCl 30mg Cap Qty 60 Ndc 80425 0086

The label for Duloxetine HCL DR 30 mg capsules by Advanced Rx of Tennessee, LLC. It includes the dosage strength (30 mg), capsule count (#60), storage instructions (20°C to 25°C), lot number 30UD820121, and an expiration date of 8/31/2021. A barcode and QR code are also present along with a caution about federal law restricting use to the prescribing person.*

FDA Label Image

Image 2

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time (days) between treatment groups. The graph shows two lines representing placebo and Duloxetine delayed-release capsules, plotting the proportion of patients relapsed against days from randomization up to 300 days.*

FDA Label Image

Image 4

A line graph comparing the percentage of patients improved by different percent improvements in pain from baseline. The graph shows three lines representing Duloxetine HCl 60 mg BID, Duloxetine HCl 60 mg QD, and placebo, with the y-axis labeled 'Percentage of Patients Improved' and the x-axis labeled 'Percent Improvement in Pain from Baseline.'*

FDA Label Image

Image 5

A line graph showing the percentage of patients improved against the percent improvement in pain from baseline. It compares three groups: Duloxetine HCL 60 mg twice daily, Duloxetine HCL 60 mg once daily, and a placebo, illustrating patient response to different dosing regimens over a range of pain improvement percentages.*

FDA Label Image

Image 6

Line chart showing percentage of patients improved plotted against percent improvement in pain from baseline, comparing Duloxetine hydrochloride (DUL) doses 20 mg, 60 mg, and 120 mg once daily to placebo. The graph illustrates trends of patient improvement at various pain reduction thresholds.*

FDA Label Image

Image 8

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows two data series: Placebo (dotted line with x markers) and Duloxetine Delayed-Release 60/120 mg once daily (solid line with diamond markers). The y-axis represents the percentage of patients improved, and the x-axis represents increasing thresholds of percent pain improvement from baseline.*

FDA Label Image

Image 9

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine delayed-release 60 mg once daily and placebo groups. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines illustrate patient improvement rates for each group.*

FDA Label Image

Image

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) between Duloxetine Delayed-Release Capsules and placebo treatments. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse, illustrating a lower relapse proportion for Duloxetine compared to placebo over approximately 200 days.*

FDA Label Image

Image3

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. Four groups are compared: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. The graph plots patient improvement percentage on the vertical axis and percent improvement in pain on the horizontal axis from 0 to 100 percent.*

FDA Label Image

Image 10

A line graph comparing the percentage of patients improved in pain from baseline between Duloxetine Delayed-Release 60/120 mg once daily and placebo groups. The x-axis shows percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved. The graph displays two lines: one solid line with diamonds for Duloxetine and one dotted line with crosses for placebo, illustrating higher patient improvement percentages with Duloxetine across the range of pain improvement thresholds.*

FDA Label Image

Logo

FDA Label Image

Structure

Chemical structure of Duloxetine HCL showing the molecular arrangement of atoms including aromatic rings, oxygen, sulfur, nitrogen, and hydrochloride components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.